1. Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. 2018;119(5):538–45.
2. Jiangsu Hengrui Medicine. Announcement on obtaining new drug certificate and drug registration approval [media release]. 31 May 2019.
http://cfi.cn/p20190531000358.html
.
3. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.
4. Jiangsu Hengrui Medicine Co. Ltd. Camrelizumab: Chinese prescribing information. Lianyungang: Jiangsu Hengrui Medicine Co. Ltd; 2019.
5. Hogan Lovells. The China Food and Drug Administration pushes forward on conditional approval and compassionate use of new drugs [media release]. 17 Jan 2018.
https://www.lexology.com/library/detail.aspx?g=73ce9342-8178-4b42-9c31-389edf0278c1
.